Key facts
- This page summarizes Jonathan E. Freeman's Form 4 filing for Phio Pharmaceuticals Corp. (PHIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 06 Feb 2026, 08:00.
Jonathan E. Freeman - 05 Feb 2026 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)
- Role
- Director
- Signature
- /s/ Lisa C. Carson, Attorney-in-Fact
- Issuer symbol
- PHIO
- Transactions as of
- 05 Feb 2026
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 06 Feb 2026, 08:00:21 UTC
- Previous filing
- 15 Sep 2025
- SEC
- View on sec.gov
Key filing fact
Jonathan E. Freeman filed Form 4 for Phio Pharmaceuticals Corp. (PHIO) on 06 Feb 2026.
Change
- Previous filing in this sequence was filed on 15 Sep 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001708133
Primary reporting owner
Freeman Jonathan E
- Relationship
- Director
- Address
- C/O PHIO PHARMACEUTICALS CORP., 411 SWEDELAND RD., STE 23-1080, KING OF PRUSSIA
- Signature
- /s/ Lisa C. Carson, Attorney-in-Fact
- Signature date
- 06 Feb 2026
Reported transactions
PHIO
transaction
Common Stock, $.0001 par value
Award
- Transaction value
- $0
- Shares
- +16,600
- Change %
- +103%
- Price
- $0.000000
- Shares after
- 32,655
- Date
- 05 Feb 2026
- Ownership
- Direct
- Footnotes
- F1, F2, F3
An asterisk next to the price means the reported price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. |
| F2 | Includes shares of common stock underlying unvested restricted stock units. |
| F3 | The number of reported securities has been adjusted to reflect prior reverse stock splits. |